Self-Amplifying RNA Cancer Vaccine Enters Human Testing for the First Time, With ITI-5000 Targeting the Risk of Triple-Negative Breast Cancer Recurrence

Triple-negative breast cancer lacks common therapeutic targets such as estrogen receptors, progesterone receptors, and HER2. Even after completing surgery, chemotherapy, or radiation therapy intended to achieve a cure, reducing the risk of recurrence remains a challenge. Immunomic Therapeutics has now advanced its investigational therapeutic vaccine ITI-5000 into its first-in-human study, seeking to use the immune system to pursue potentially remaining cancer cells after standard treatment has ended.

On July 20, the company announced that the first participant had received ITI-5000 in the Phase 1 trial and completed initial post-administration monitoring. As of the announcement, no serious adverse events or safety concerns had been reported. However, short-term observation of a single participant can only confirm that the trial has begun; it is not sufficient to determine the vaccine’s overall safety, much less whether it can prevent recurrence.

ITI-5000 is a self-amplifying RNA vaccine. After the RNA enters cells, it can replicate for a period of time, thereby increasing antigen expression. It encodes two tumor-associated antigens, CT83 and the HERV-K envelope protein, and uses the UNITE platform to link the antigens with lysosome-associated membrane protein 1, or LAMP-1. The design is intended to direct the antigens into intracellular antigen-processing pathways and thereby induce tumor-targeting T-cell responses. Whether these mechanisms can produce a sufficiently strong and durable immune effect in human patients is precisely what the study needs to verify.

The study registered as NCT07652242 is a multicenter, open-label, first-in-human trial expected to enroll approximately 60 patients with stage II to III triple-negative breast cancer who have completed standard curative treatment. The first part uses a dose-escalation design, separately testing 1 microgram and 10 micrograms of ITI-5000 as monotherapy, administered by intramuscular injection once every 28 days for a total of three vaccinations. The research team will select the subsequent dose based on dose-limiting toxicity, safety, and tolerability.

If the monotherapy stage passes safety review, the second part will combine the selected dose of ITI-5000 with the immune checkpoint inhibitor pembrolizumab. In addition to adverse events and the maximum tolerated dose, the study will explore vaccine-induced immune responses and changes in circulating tumor DNA. The latter two are exploratory measures and cannot replace clinical efficacy endpoints such as recurrence rates or survival.

The significance of this study lies in bringing self-amplifying RNA technology into the post-treatment setting for triple-negative breast cancer, rather than proving that the new therapy is already effective. The current trial has no control group, and the Phase 1 study is designed primarily to assess dosage and safety. Even if immune responses or reductions in circulating tumor DNA are subsequently observed, larger controlled studies with longer follow-up will still be required to confirm whether the treatment truly reduces recurrence and improves survival.